Ticker: RPRX

Royalty Pharma (RPRX) buys up to $950M royalty stake in Amgen's (AMGN) KRAS G12C lung‑cancer drug sotorasib (Lumakras), converting future sales into cash - a bet on trials, label expansion and pricing.

Royalty Pharma plc (NASDAQ: RPRX) recently filed its Q2 2025 financial results, revealing a mix of positive outlooks and challenges. Key Financial Highlights: Total revenues: $578.7 million, up from $537.3 million year-over-year, a 7.7% increase. Income from financial royalty assets: $550.4 mill...